NCT06972355Recruiting
Efficacy of Treadmill Walking With Hidden Vision for Rehabilitation in the Subacute Phase of Stroke
Efficacy of Treadmill Walking With Hidden Vision for Rehabilitation in the Subacute Phase of Stroke, Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 1 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Objective: The aim of this study is to compare the efficiency of vision-obscured versus vision-retained treadmill gait training in subacute post-stroke patients. Methodology: Thirty-six patients with stroke (ischemic or hemorrhagic) less than six months old will be included and randomized into two parallel groups. The experimental group will undergo treadmill gait training using an opaque mask, combined with body weight reduction (Lite Gait® harness). The control group will follow the same walking protocol, but with their eyes open. Each session will last 20 minutes, integrated into one hour of rehabilitation, at a rate of three sessions per week for six weeks. Assessment will include single- and double-task walking speed, balance parameters and proprioception. Expected results: The hypothesis is that visual deprivation will stimulate the proprioceptive and vestibular systems to a greater extent, resulting in benefits for postural balance, walking and proprioception. The main hypothesis will be the improvement in the difference between single-task and double-task walking speed. Analyses will be conducted on an intention-to-treat basis, using statistical tests adapted to the nature of the variables. Conclusion: This study could highlight the value of temporary visual suppression as a therapeutic lever in stroke rehabilitation.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 25 Apr 2025
- Start date
- Jun 2025
- Primary completion date
- Jun 2027
- Lead sponsor
- Centre Hospitalier Régional Metz-Thionville
- Diseases
- Stroke
- NCT number
- NCT06972355
What you commit to
- Study type: Interventional
- Planned participants: 36
- From Jun 2025 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Inability to physically participate in intensive rehabilitation due to severe, unstabilized and comorbidities (heart, lung, kidney disease or diabetes), severe psychiatric disorders cancer active or under treatment.
Other
- Patients weighing over 200 kg (maximum weight permitted for use of the Lite Gait ®),
- Patients with impaired vision:
- Best corrected visual acuity below 5/10 on patient examination
- Homonymous lateral hemianopia, quadranopia.
- Patients participating in other interventional research,
- Pregnant or breast-feeding women,
- Patients under guardianship.
Who the study is looking for
- 18 years of age or older,
- With a confirmed diagnosis of ischemic or hemorrhagic stroke in sub-acute phase (stroke less than 6 months old),
- With NIHSS scores between 1 and 15 and MoCA scores between 18 and 30
- With a physiotherapy prescription for post Stroke rehabilitation
- Able to walk for 20 min on a treadmill with weight reduction with pauses, able to maintain bipodal balance, able to maintain bipodal balance with eyes open and closed for 30 seconds,
- Having expressed free, informed and written consent
- Affiliated with a social security scheme.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHR Metz-Thionville Hopital Legouest Coordinator of this site? Confirm its status | Metz | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.